Hutchmed China Ltd ADR (HCM)

$20.17 0.79 (3.77%)

16:00 EDT HCM Stock Quote Delayed 30 Minutes

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Mar 13, 2024

Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!

Beware! 3 Machine Learning Stocks Waving Massive Red Flags Right Now

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

More Articles

Volume:

Previous Close -

Market Cap 17.57B

PE Ratio 168.08

EPS 0.12

Volume (Avg. Vol.) 48,119

Day's Range $20.06 - $20.50

52-Week Range $10.68 - $21.92

Dividend & Yield N/A (N/A)

HCM Stock Predictions, Articles, and Hutchmed China Ltd ADR News

From InvestorPlace
From the Web

7 Chinese Stocks to Sell While You Still Can

By Muslim Farooque, InvestorPlace Contributor Sep 2, 2022

These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure

HFCAA News: 128 Chinese Stocks the SEC Could Delist

By William White, InvestorPlace Writer May 5, 2022

The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.

7 Biotech Stocks to Buy With Key Catalysts for April

By Shanthi Rexaline Apr 5, 2022

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs

By Brian Paradza, CFA Mar 28, 2022

Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.

By Chris MacDonald, InvestorPlace Contributor Mar 25, 2022

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?

By William White, InvestorPlace Writer Mar 11, 2022

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jul 28, 2021

Good morning! We're halfway through the week and still going strong with a look at the biggest pre-market stock movers for Wednesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jun 30, 2021

Good morning! We're taking a look at the biggest pre-market stock movers for Wednesday and that includes the winners and losers.

Hutchison China MediTech reports FY results (NASDAQ:HCM)

From Seeking Alpha Feb 28, 2024

Hutchison China MediTech (HCM) reports FY 2023 results, with revenue beating expectations and increased cash balance for self-sustaining growth.

Hutchmed grants exclusive license to Inmagene for two drug candidates (NASDAQ:HCM)

From Seeking Alpha Feb 2, 2024

Hutchmed (HCM) has granted an exclusive, worldwide, royalty-bearing license to partner Inmagene to develop drug candidates IMG-007 and IMG-004. Read more here.

Chinese regulators accept HUTCHMED application for solveplenib (NASDAQ:HCM)

From Seeking Alpha Jan 11, 2024

HUTCHMED (HCM) said Chinese regulators have accepted its NDA with priority review for its drug solveplenib for the treatment of primary immune thrombocytopenia.

Hutchmed says Chinese Phase 3 sovleplenib study meets primary endpoint (HCM)

From Seeking Alpha Aug 21, 2023

Hutchmed (HCM) said that a Chinese Phase 3 study of its drug sovleplenib in the treatment of primary immune thrombocytopenia met its primary endpoint. Read more here.

Hutchison China MediTech Non-GAAP EPS of $0.97, revenue of $532.9M (NASDAQ:HCM)

From Seeking Alpha Jul 31, 2023

Hutchison China MediTech press release (HCM): 1H Non-GAAP EPS of $0.97.Revenue of $532.9M (+163.8% Y/Y).Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED...

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), MacroGenics (MGNX) and HUTCHMED (HCM)

From TipRanks Aug 9, 2022

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viatris (

ADVERTISEMENT